LGND News and Press, Ligand Pharmaceuticals Incorporated From 03/16/21

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event. For further details see: Ligand Pharmaceuticals (LGND) Investor Presentation - Slideshow

A symmetrical triangle pattern has emerged in the chart of Ligand Pharmaceuticals (LGND). If the stock rises through the down trending resistance, a breakout could occur. On the other hand, if LGNC falls through the up trending support line, a breakdown could occur. Read more to learn how to ...

Presented are the top-ranked stocks in our research that have beat analyst earnings estimates in each of the past four quarters. High-scoring stocks with a track record of beating on earnings can provide a great hunting ground for new stock ideas. Ideas range across most sectors, ...

S3 Partners highlights three stocks on its list of 200 names with short-squeeze pressure. S3's Ihor Dusaniwsky notes Virgin Galactic Holdings ([[SPCE]] -1.6%) has a large short interest of $2.02B and a stock borrow cost over 2% fee. "We've seen $271 million of short covering over the last thi...

It's not often a textbook short squeeze creates a classic bubble. A stock with significant bets against it starts rising, forcing those who are short to "cover," or buy shares themselves. The rising price attracts more and more attention until a frenzy of buyers bid the stock up to irra...

High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...

Ligand Pharmaceuticals Incorporated (LGND) Q4 2020 Earnings Conference Call February 3, 2021 8:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance and Chief Financial Officer Matt Foehr - ...

Image source: The Motley Fool. Ligand Pharmaceuticals Inc (NASDAQ: LGND) Q4 2020 Earnings Call Feb 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcrip...

Ligand Pharmaceuticals (LGND): Q4 Non-GAAP EPS of $1.62 beats by $0.63; GAAP EPS of $0.35 misses by $0.05.Revenue of $70M (+159.3% Y/Y) beats by $16.06M.FY2021 guidance: Ligand now expects total revenues to be approximately $291 million vs. $288.39M and adjusted diluted EPS to be approximatel...

Raises 2021 Financial Guidance Conference Call Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and pr...